AXP
81
4
PM
66
23
URI
58
9
MS
73
3
LLY
60
6
ADBE
50
3
PAYX
53
2
PRU
53
2
CSCO
57
3
RCL
69
7
INTU
69
6
NRG
75
3
SRE
54
-2
IP
36
-6
SCHW
61
3
AN
54
4
SBUX
50
-2
TJX
58
-3
VFC
17
2
PEG
48
-2
AXP
81
4
PM
66
23
URI
58
9
MS
73
3
LLY
60
6
ADBE
50
3
PAYX
53
2
PRU
53
2
CSCO
57
3
RCL
69
7
INTU
69
6
NRG
75
3
SRE
54
-2
IP
36
-6
SCHW
61
3
AN
54
4
SBUX
50
-2
TJX
58
-3
VFC
17
2
PEG
48
-2
Financhill
Back

Clinuvel Pharmaceuticals 10K Form

Sell
39

CLVLY
Clinuvel Pharmaceuticals

Last Price:
9.76
Seasonality Move:
2.82%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CLVLY News And Ratings

See the #1 stock for the next 7 days that we like better than CLVLY

CLVLY Financial Statistics

Sales & Book Value

Annual Sales: $52.69M
Cash Flow: $0
Price / Cash Flow: 0
Annual Sales: $2.43
Price / Book: 4.02

Profitability

EPS (TTM): 0.37910
Net Income (TTM): $19.95M
Gross Margin: $46.78M
Return on Equity: 18.4%
Return on Assets: 15.69%

Clinuvel Pharmaceuticals Earnings Forecast

Key Clinuvel Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 19 years for CLVLY is 88.78%.
  • The Selling, General & Administrative Expenses for CLVLY have been equal to 28.81% of Gross Profit Margin.
  • The Research & Development expenses have been 259.75% of Revenue.
  • The Interest Expense is 10.43% of Operating Income.
  • The Net Earning history of CLVLY is 39.08% of Total Revenues.
  • Per Share Earnings over the last 24 years have been positive in 13 years.

Clinuvel Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: OTCM
Industry: Biotechnology
Sector: Health Care
Current Symbol: CLVLY
Website: clinuvel.com

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 6.86
Quick Ratio: 6.38

Price-to-Earnings

Trailing P/E Ratio: 24.54
Forward P/E Ratio: 0

CLVLY Technical Analysis vs Fundamental Analysis

Sell
39
Clinuvel Pharmaceuticals (CLVLY) is a Sell

Is Clinuvel Pharmaceuticals a Buy or a Sell?